431 related articles for article (PubMed ID: 24064337)
1. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.
Farfel-Becker T; Vitner EB; Kelly SL; Bame JR; Duan J; Shinder V; Merrill AH; Dobrenis K; Futerman AH
Hum Mol Genet; 2014 Feb; 23(4):843-54. PubMed ID: 24064337
[TBL] [Abstract][Full Text] [Related]
2. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease.
Nilsson O; Svennerholm L
J Neurochem; 1982 Sep; 39(3):709-18. PubMed ID: 7097276
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
5. Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model.
Dasgupta N; Xu YH; Li R; Peng Y; Pandey MK; Tinch SL; Liou B; Inskeep V; Zhang W; Setchell KD; Keddache M; Grabowski GA; Sun Y
Hum Mol Genet; 2015 Dec; 24(24):7031-48. PubMed ID: 26420838
[TBL] [Abstract][Full Text] [Related]
6. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease.
Farfel-Becker T; Vitner EB; Pressey SN; Eilam R; Cooper JD; Futerman AH
Hum Mol Genet; 2011 Apr; 20(7):1375-86. PubMed ID: 21252206
[TBL] [Abstract][Full Text] [Related]
7. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
Xu YH; Sun Y; Ran H; Quinn B; Witte D; Grabowski GA
Mol Genet Metab; 2011 Apr; 102(4):436-47. PubMed ID: 21257328
[TBL] [Abstract][Full Text] [Related]
8. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.
Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L
J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774
[TBL] [Abstract][Full Text] [Related]
9. Neuronal forms of Gaucher disease.
Vitner EB; Futerman AH
Handb Exp Pharmacol; 2013; (216):405-19. PubMed ID: 23563668
[TBL] [Abstract][Full Text] [Related]
10. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.
Conradi NG; Sourander P; Nilsson O; Svennerholm L; Erikson A
Acta Neuropathol; 1984; 65(2):99-109. PubMed ID: 6524300
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
12. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
13. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.
Karageorgos L; Hein L; Rozaklis T; Adams M; Duplock S; Snel M; Hemsley K; Kuchel T; Smith N; Hopwood JJ
Neurobiol Dis; 2016 Jul; 91():143-54. PubMed ID: 26976737
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
[TBL] [Abstract][Full Text] [Related]
16. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease.
Blumenreich S; Yaacobi C; Vardi A; Barav OB; Vitner EB; Park H; Wang B; Cheng SH; Sardi SP; Futerman AH
J Neurochem; 2021 Mar; 156(5):692-701. PubMed ID: 32743826
[TBL] [Abstract][Full Text] [Related]
17. Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease.
Zigdon H; Meshcheriakova A; Farfel-Becker T; Volpert G; Sabanay H; Futerman AH
FEBS Lett; 2017 Mar; 591(5):774-783. PubMed ID: 28186340
[TBL] [Abstract][Full Text] [Related]
18. Induction of the type I interferon response in neurological forms of Gaucher disease.
Vitner EB; Farfel-Becker T; Ferreira NS; Leshkowitz D; Sharma P; Lang KS; Futerman AH
J Neuroinflammation; 2016 May; 13(1):104. PubMed ID: 27175482
[TBL] [Abstract][Full Text] [Related]
19. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.
Cabrera-Salazar MA; Deriso M; Bercury SD; Li L; Lydon JT; Weber W; Pande N; Cromwell MA; Copeland D; Leonard J; Cheng SH; Scheule RK
PLoS One; 2012; 7(8):e43310. PubMed ID: 22912851
[TBL] [Abstract][Full Text] [Related]
20. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy.
Boddupalli CS; Nair S; Belinsky G; Gans J; Teeple E; Nguyen TH; Mehta S; Guo L; Kramer ML; Ruan J; Wang H; Davison M; Kumar D; Vidyadhara DJ; Zhang B; Klinger K; Mistry PK
Elife; 2022 Aug; 11():. PubMed ID: 35972072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
